ANSI certification expected soon
This article was originally published in The Gold Sheet
Executive Summary
Irwin Silverstein, vice-president and chief executive officer of International Pharmaceutical Excipients Auditing Inc., said that he expects the organization's third-party audit program of excipient suppliers to be certified by the American National Standards Institute by "the end of the first quarter of this year." He expects certification to ensure greater legitimacy - and acceptance - of IPEA's audit program among the pharmaceutical industry and FDA. He noted that "we're starting to gain more acceptance" with respect to third-party review of excipient suppliers. "2009 was a good year for the third-party certification program, it was a successful year." Silverstein further noted that "I think the agency sees the handwriting on the wall" with respect to third-party certification. "We think FDA will accept ANSI accreditation. The agency is one of the final arbiters. If ANSI says we have a good system, so should FDA." IPEA provides third-party audits of excipient manufacturers and auditor training and is an independent subsidiary of IPEC-Americas
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.